Indications
Trevicta, a 3 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly paliperidone palmitate injectable product.
Composition
- Active substance
- paliperidone palmitate
- International name (INN)
- paliperidone
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Trevicta (previously Paliperidone Janssen)
- Active substance
- paliperidone palmitate
- ATC code
- N05AX13
- Group
- Nervous system
- Therapeutic area
- Schizophrenia
- Marketing authorisation holder
- Janssen-Cilag International NV